Mushtaq Syed, MD
Endocrinology, Diabetes & Metabolism · Indiana, PANPI 1649230855
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,859 of the $83,048 with a category attached, or 74.5%. 40 manufacturers reported payments, led by AstraZeneca at 36.6% of the total. Reporting peaked in 2019 at $33,886 and has fallen 92.9% since, to $2,399 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 584 payments — averaging $142.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$30K
- Novo Nordisk$29K
- Ascendis Pharma Endocrinology Inc$8K
- Ascensia Diabetes Care US Inc.$4K
- Amgen$3K
- Medtronic$2K
- plus $5K from 34 others
Across 78 payments — averaging $3000.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$93K
- Takeda Pharmaceuticals U.S.A., Inc.$50K
- Lexicon Pharmaceuticals, Inc.$46K
- AstraZeneca$24K
- AbbVie$11K
- Shire North American Group Inc$8K
- plus $2K from 1 others
What the payments were for
- Consulting fees$4,6436%
- Speaking & faculty fees$61,85974%
- Travel & lodging$5,6257%
- Food & beverage$10,75013%
- Education$690%
- Gifts$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 69 | $30,397 |
| Novo Nordisk | 141 | $29,414 |
| Ascendis Pharma Endocrinology Inc | 14 | $8,435 |
| Ascensia Diabetes Care US Inc. | 8 | $4,250 |
| Amgen(2 entities) | 34 | $2,840 |
| Medtronic(2 entities) | 24 | $2,293 |
| Lilly USA, LLC | 62 | $992 |
| Boehringer Ingelheim | 25 | $418 |
| Merck | 33 | $375 |
| Sanofi-aventis U.S. LLC | 24 | $369 |
| Mannkind Corporation | 10 | $318 |
| Cequr Corporation | 4 | $306 |
| Bigfoot Biomedical Inc | 6 | $285 |
| Insulet Corporation | 13 | $280 |
| Johnson & Johnson | 18 | $269 |
| Abbott | 9 | $254 |
| Averitas Pharma Inc. | 13 | $242 |
| Bayer | 11 | $202 |
| Xeris Pharmaceuticals, Inc. | 8 | $145 |
| Tandem Diabetes Care, Inc. | 6 | $112 |
| Corcept Therapeutics | 6 | $103 |
| Novartis | 5 | $90 |
| Dexcom, Inc. | 5 | $87 |
| AbbVie | 5 | $85 |
| GRT US Holding, Inc. | 4 | $67 |
| Valeritas, Inc. | 3 | $55 |
| BETA Bionics, Inc. | 3 | $52 |
| Radius Health, Inc. | 3 | $43 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Antares Pharma, Inc. | 2 | $38 |
| Amarin Pharma, Inc. | 3 | $36 |
| Zealand Pharma US, Inc. | 2 | $32 |
| Sequel Med Tech, LLC | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $23 |
| Madrigal Pharmaceuticals | 1 | $16 |
| Lifescan, Inc. | 1 | $15 |
| Companion Medical, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Nevro Corp. | 1 | $13 |
| Kvk-tech, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$29,102
- Ozempic$9,997
- Tresiba$7,438
- RYBELSUS$5,630
- Victoza$2,093
- Xultophy 100/3.6$1,755
- Minimed 670G System$1,750
- TEPEZZA$146
- SKYTROFA$129
- FREESTYLE LIBRE 3$124
- CeQur Simplicity$123
- UNITY DIABETES MANAGEMENT SYSTEM$119
How this compares
$83,048 in reported general payments places this provider in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 876 | $972,165 |
| OzempicSemaglutide | 796 | $902,294 |
| JardianceEmpagliflozin | 421 | $336,910 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 382 | $303,717 |
| FarxigaDapagliflozin Propanediol | 262 | $238,258 |
| Xigduo XrDapaglifloz Propaned/Metformin | 257 | $175,946 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 73 | $169,095 |
| MounjaroTirzepatide | 137 | $158,512 |
| ProliaDenosumab | 98 | $152,622 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 127 | $123,006 |
| RybelsusSemaglutide | 107 | $106,967 |
| Humalog Kwikpen U-200Insulin Lispro | 38 | $90,690 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 48 | $81,391 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 138 | $79,288 |
| TymlosAbaloparatide | 14 | $72,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog | $992 | $1,198,7891,108 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $29,414 | $1,109,2851,043 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy, Trijardy Xr | $418 | $797,6681,012 claims |
| AmgenEvenity (2 Syringes), Prolia | $2,840 | $321,717171 claims |
| AstraZenecaFarxiga | $30,397 | $238,258262 claims |
| Radius Health, Inc.Tymlos | $43 | $72,03514 claims |
| Johnson & JohnsonInvokana | $269 | $61,12872 claims |
| MerckJanuvia | $375 | $26,13431 claims |
| BayerKerendia | $202 | $23,17136 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $369 | $15,31921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Indiana
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
- Mitchell LazarPhiladelphia$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.